Company intelligence / Profile preview

Luventix

Henderson, Nevada, United Statesluventix.com ↗

Ownership: Private
Employees: ~15
Development stage: Preclinical

Overview

Luventix has demonstrated high accuracy in detecting colon cancer from urine samples using its proprietary AI-driven metabolomic analysis platform. The colon cancer model achieved an AUC of 0.978 in validation studies. Additional IRB-approved clinical studies are underway targeting Crohn's disease, celiac disease, and SIBO.

Therapeutic areas: OncologyGastroenterology
Modalities: Diagnostic test (urine-based)Artificial intelligence/machine learning-enabled diagnostics
Industry: Metabolite Diagnostics

Partnerships

Gradient Biomodelling LLCPark City Venture PartnersAcademic collaborations with UC Davis Genome Center and University College London Cancer Trials Centre through advisory board members

Beyond the preview

Go deeper on Luventix.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Luventix.

Explore the full profile